Payment overview · 2025
General Payments
$1,264.47
65 reported records · 23 companies
Healthcare provider profile · identity verified
Tami R Bruce, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MESA, AZ · NPI 1548324254
Verified facts
What the public records show
CMS Open Payments records show Tami R Bruce, MD received $1,264.47 in general payments during 2025 across 65 reported records.
GENZYME CORPORATION accounted for 13.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $171.26 | 13.5% | 6 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $157.77 | 12.5% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.21 | 11.5% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $115.96 | 9.2% | 6 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $65.68 | 5.2% | 4 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $64.18 | 5.1% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $53.95 | 4.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.79 | 4.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $47.99 | 3.8% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $45.77 | 3.6% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $43.28 | 3.4% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $38.42 | 3.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.50 | 2.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.35 | 2.5% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $30.89 | 2.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $27.04 | 2.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.88 | 2.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $23.07 | 1.8% | 1 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $22.64 | 1.8% | 1 | 2025 |
| Biocon Biologics Inc | Unresolved — no canonical attribution shown | $21.66 | 1.7% | 1 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $21.53 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.13 | 1.5% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $6.52 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,264.47 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $214.54 | 8 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $157.77 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $115.96 | 6 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $76.78 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.43 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $65.68 | 4 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $64.18 | 3 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $64.18 | 3 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $64.18 | 3 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $64.18 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $53.95 | 2 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $45.77 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $38.42 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $31.35 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $30.89 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| Yesintek Normalized: yesintek |
Biological | Biocon Biologics Inc | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $6.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 531 | 155 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 462 | 158 |
| Atorvastatin Calcium | Atorvastatin Calcium | 431 | 138 |
| Losartan Potassium | Losartan Potassium | 329 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 283 | 88 |
| Lisinopril | Lisinopril | 266 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 50 |
| Gabapentin | Gabapentin | 153 | 50 |
| Simvastatin | Simvastatin | 149 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 40 |
| Metformin Hcl Er | Metformin Hcl | 136 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 45 |
| Montelukast Sodium | Montelukast Sodium | 117 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 36 |
| Omeprazole | Omeprazole | 112 | 35 |
| Ezetimibe | Ezetimibe | 104 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 30 |
| Alendronate Sodium | Alendronate Sodium | 100 | 34 |
| Trazodone Hcl | Trazodone Hcl | 89 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 47 |
| Sertraline Hcl | Sertraline Hcl | 78 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 20 |
| Potassium Chloride | Potassium Chloride | 72 | 25 |
| Metformin Hcl | Metformin Hcl | 70 | 23 |
| Jardiance | Empagliflozin | 65 | 20 |
| Mirtazapine | Mirtazapine | 61 | 18 |
| Allopurinol | Allopurinol | 59 | 19 |
| Ozempic | Semaglutide | 59 | 15 |
| Furosemide | Furosemide | 55 | 27 |
| Synthroid | Levothyroxine Sodium | 54 | 17 |
| Carvedilol | Carvedilol | 53 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 13 |
| Fenofibrate | Fenofibrate,micronized | 45 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 12 |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Celecoxib | Celecoxib | 40 | 15 |
| Famotidine | Famotidine | 40 | 16 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 40 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 16 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 12 |
| Valacyclovir | Valacyclovir Hcl | 34 | 15 |
| Eliquis | Apixaban | 33 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Atenolol | Atenolol | 31 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Estradiol | Estradiol | 20 | 11 |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Meloxicam | Meloxicam | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Indapamide | Indapamide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Glipizide | Glipizide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,264.47 · 65 records | GENZYME CORPORATION | CHARTIS CATHETER, DUPIXENT, FREESTYLE LIBRE 3, Hillrom - Vest System Model 105 Home Care, IBSRELA, JASCAYD, KEVEYIS, LUNA, OMVOH, Ohtuvayre, Ozempic, PULMONX CHARTIS TABLET CONSOLE, Rybelsus, SMARTVEST, Sucraid, TRELEGY ELLIPTA, TREMFYA, Tyvaso, VEGZELMA, Wegovy, XIFAXAN, YUPELRI, Yesintek, ZENPEP, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, ZERBAXA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error